Does Ovid Therapeutics (OVID) disclose any related-party transactions with Anna Greka?

Ovid Therapeutics states there are no relationships or transactions involving Anna Greka that require disclosure under Item 404(a) of Regulation S-K. The company also notes there are no arrangements or understandings with other persons regarding her selection as a director.

Ovid Therapeutics adds Anna Greka to its board

Ovid Therapeutics Inc. appointed Anna Greka, M.D., Ph.D. to its Board of Directors as a Class III director, effective June 15, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Ovid Therapeutics Inc. appointed Anna Greka, M.D., Ph.D. to its Board of Directors as a Class III director, effective June 15, 2026. Her term will run until the company’s 2029 annual meeting of stockholders, at which point she would be eligible for re-election.

With her appointment, the Board will expand to seven directors. Dr. Greka will serve on the Compensation Committee and the Science and Technology Committee. She is a Professor of Medicine at Harvard Medical School and holds multiple leadership roles at the Broad Institute, bringing deep scientific and biotech advisory experience.

As a non-employee director, Dr. Greka will receive compensation under Ovid’s standard non-employee director compensation policy and has entered into the company’s standard indemnification agreement. The company states there are no related-party relationships or arrangements requiring disclosure under Regulation S-K Item 404(a).

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective appointment date: June 15, 2026 Board size after change: 7 directors Director term end: 2029 annual meeting +1 more

4 metrics

Effective appointment date June 15, 2026 Date Anna Greka joins the Board

Board size after change 7 directors Board size effective June 15, 2026

Director term end 2029 annual meeting End of Class III director term

Director age 50 years Age of Anna Greka at appointment

Key Terms

Class III director, Nominating and Corporate Governance Committee, non-employee director compensation policy, indemnification agreement, +1 more

5 terms

Class III director regulatory

"appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company"

A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.

Nominating and Corporate Governance Committee regulatory

"upon recommendation of the Nominating and Corporate Governance Committee of the Board"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

non-employee director compensation policy financial

"compensation for her board and committee service consistent with the Company’s non-employee director compensation policy"

indemnification agreement regulatory

"The Company and Dr. Greka also entered into the Company’s standard form of indemnification agreement."

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

Item 404(a) of Regulation S-K regulatory

"requiring disclosure under Item 404(a) of Regulation S-K."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ovid Therapeutics (OVID) announce in this 8-K filing?

Ovid Therapeutics announced the appointment of Anna Greka, M.D., Ph.D., as a Class III director effective June 15, 2026. Her term will run until the company’s 2029 annual meeting of stockholders, and the Board will increase to seven members.

Who is Anna Greka and what is her background relevant to OVID?

Anna Greka is a Professor of Medicine at Harvard Medical School and a leader at the Broad Institute. She has extensive experience founding, advising and working with biopharmaceutical companies, which aligns with Ovid Therapeutics’ focus on biotechnology and drug development.

What board committees will Anna Greka serve on at Ovid Therapeutics (OVID)?

Anna Greka will serve on Ovid Therapeutics’ Compensation Committee and its Science and Technology Committee. These roles place her directly in oversight of executive pay and the company’s scientific and technological direction, leveraging her academic and biotech experience.

When does Anna Greka’s term as Ovid Therapeutics (OVID) director end?

Anna Greka’s term as a Class III director will expire at Ovid Therapeutics’ 2029 annual meeting of stockholders. At that meeting, shareholders could vote on her re-election under the company’s standard director nomination and election process.

How will Anna Greka be compensated for her role at Ovid Therapeutics (OVID)?

Anna Greka will receive compensation consistent with Ovid Therapeutics’ non-employee director compensation policy. The company refers investors to its April 27, 2026 definitive proxy statement, which describes director compensation under the Executive Officer and Director Compensation—Director Compensation section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/03/2026 - 07:03 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 29, 2026

Ovid Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-38085	46-5270895
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

441 Ninth Avenue, 14th Floor New York, New York		10001
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646-661-7661

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

OVID

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s 2029 annual meeting of stockholders. Effective as of June 15, 2026, the Board will consist of seven directors. Dr. Greka was appointed as a member of the Compensation Committee and Science and Technology Committee of the Board, effective as of June 15, 2026.

Dr. Greka, age 50, currently serves as Professor of Medicine at Harvard Medical School and Mass General Brigham. She joined Harvard Medical School as an Assistant Professor in 2012, and has since served in roles of increasing responsibility. Dr. Greka also currently holds several roles at the Broad Institute of MIT and Harvard, including Executive Leadership Team Member (since April 2024), Founding Director and Chair of Ladders to Cures Scientific Accelerator (since July 2023), Founding Director of Kidney Disease Initiative (since February 2016) and Core / Institute Faculty Member (since February 2016). Additionally, Dr. Greka has served as a Venture Advisor to Aditum Bio, a biotech focused venture capital firm, since 2013, founded and served as an Advisor to Goldfinch Bio, a clinical-stage biotech company, from 2015 to 2023 and founded and advised numerous other biopharmaceutical companies. Dr. Greka received her M.D. from the Harvard-MIT program in Health Sciences and Technology, Ph.D. from Harvard Medical School and A.B. from Harvard University.

Dr. Greka will receive compensation for her board and committee service consistent with the Company’s non-employee director compensation policy, as described under the caption “Executive Officer and Director Compensation—Director Compensation” in the Company’s most recent definitive proxy statement, filed with the Securities and Exchange Commission on April 27, 2026, which is incorporated herein by reference.

The Company and Dr. Greka also entered into the Company’s standard form of indemnification agreement. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Dr. Greka for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts actually and reasonably incurred by her in any action or proceeding arising out of her service as a director of the Company.

There are no arrangements or understandings between Dr. Greka and any other persons pursuant to which Dr. Greka was selected as a director. There are no relationships or transactions in which Dr. Greka has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



OVID THERAPEUTICS INC.

Date: June 3, 2026	By:	/s/ Margaret Alexander
		Margaret Alexander
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents